TOKYO – Despite the weakening yen and uncertainties in the drug pricing system, Japan's pharmaceutical market is still the most attractive in the Asia-Pacific region and only second to the U.S. globally, according to a recent report by BMI Research. The market's size and purchasing power as well as the strength of the regulatory environment makes the outlook of Japan's pharmaceutical industry highly promising.